**Background:** Acanthamoeba species are environmental hosts for various microorganisms and can cause Acanthamoeba keratitis (AK), a progressive corneal infection often associated with coinfections involving bacteria. The presence of bacterial endosymbionts has been linked to increased virulence, but the role of naturally acquired intracellular bacteria in AK severity in vivo remained unclear. This study investigated whether naturally occurring intracellular Pseudomonas aeruginosa within Acanthamoeba enhances keratitis in a rat model.
**Methods:** Acanthamoeba isolates were recovered from domestic tap water (AK1) and from a corneal swab of an AK patient (AK11), both confirmed as genotype T4F by sequencing. The AK1 strain was found to harbor intracellular P. aeruginosa (AK1-PA) by 16S rRNA PCR, MALDI-TOF MS, and FISH. TEM showed bacteria within phagolysosome-like structures and undergoing binary fission. Metabolic activity of intracellular bacteria was confirmed using alkDala labeling. The motility of AK1-PA (swimming, swarming, twitching) was compared to wild-type PA01, and the exoU and exoS genes were detected by PCR. Survival of AK1-PA versus PA01 was assessed in human monocyte-derived macrophages (hMDMs) by CFU counting at 3, 6, 12, and 24 h post-infection. In two phases, rats received intrastromal injections of: (Phase I) Acanthamoeba without intracellular bacteria (group A, n=4) or Acanthamoeba with intracellular P. aeruginosa (group B, n=4); (Phase II) Acanthamoeba re-isolated from group B corneas (AK10, group C, n=3) or P. aeruginosa alone re-isolated from group B (group D, n=3, ~4×10^4 cells). Clinical scores were assessed daily for 5 days using slit lamp. Histopathology (H&E, calcofluor white), MPO assay, and re-isolation of organisms were performed.
**Key Results:** The Acanthamoeba AK1 strain contained an average of 4±2.2 intracellular P. aeruginosa per trophozoite. AlkDala labeling confirmed the bacteria were metabolically active. AK1-PA possessed the exoU gene but not exoS; motility did not differ significantly from PA01. In hMDMs, AK1-PA showed significantly higher intracellular survival: at 3 h, >4-fold greater CFU than PA01 (p<0.05); at 24 h, ~3-fold greater (p<0.05). Confocal microscopy at 6 and 12 h showed significantly higher bacterial load per macrophage with AK1-PA (p<0.05). In vivo, group B (Acanthamoeba with intracellular P. aeruginosa) developed severe keratitis with ring infiltrate, ulceration, and corneal opacity within 48 h, with mean clinical scores significantly higher than group A at all time points (p≤0.05 to p≤0.0001). Group A (Acanthamoeba alone) showed only mild focal infiltrates. Histology of group B corneas revealed complete epithelial/endothelial collapse, hemorrhagic necrosis, and inflammatory infiltrates, while group A showed only focal necrosis. CFW staining and laser microdissection confirmed Acanthamoeba cysts in group B corneas. Re-isolated trophozoites (AK10) from group B had no intracellular bacteria. In phase II, group D (P. aeruginosa alone) developed moderate keratitis but significantly lower clinical scores than group B (p<0.05). Group C (AK10) showed mild keratitis. MPO levels were highest in group B (1312.3 ng/mL), compared to group D (791.3 ng/mL), group A (367.5 ng/mL), and group C (191.6 ng/mL); differences between group B and others were significant (p<0.05). The mean clinical scores of group C were significantly higher than group A (p<0.05), suggesting increased virulence after corneal passage.
**Clinical Implications:** The study demonstrates that Acanthamoeba harboring live intracellular P. aeruginosa induces significantly more severe keratitis in rats than Acanthamoeba alone or bacteria alone. The ability of these bacteria to survive and replicate within human macrophages suggests a potential for enhanced pathogenicity. The release of bacteria from amoebae in the cornea may drive polymicrobial keratitis. Routine assessment for intracellular bacteria in corneal isolates of Acanthamoeba may improve diagnosis and treatment, potentially warranting adjunctive antibiotic therapy.